Li Zongru, Peng Li, Li Yongjie, Zhang Jun, Jiang Qian
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Department of Neurology, Peking University People's Hospital, Beijing, China.
Leuk Lymphoma. 2022 Oct;63(10):2352-2363. doi: 10.1080/10428194.2022.2070912. Epub 2022 May 11.
Cognitive function was assessed in patients with chronic myeloid leukemia in the chronic phase (CML-CP) receiving tyrosine kinase inhibitor (TKI) therapy using the Montreal Cognitive Assessment (MoCA). Cross-sectional assessments of 100 newly diagnosed patients and 584 patients receiving TKI therapy for >1 year showed that 31 (31.0%) and 191 (32.7%) patients had mild cognitive impairment, respectively. In the multivariable analyses, higher percentages of blood blasts were associated with a worse MoCA score at diagnosis [ = -0.29, 95% confidence interval (-0.54, -0.03), = .027]; deeper molecular response [versus < major molecular response, = 0.74 (0.07, 1.40), = .029], better MoCA score on TKI therapy. Increased MoCA scores were observed after 12 months of TKI therapy in 42 patients who were regularly followed up ( = .005). Lower tumor burden is associated with better cognitive function in CML-CP patients both at diagnosis and during TKI therapy.
使用蒙特利尔认知评估量表（MoCA）对处于慢性期的慢性髓性白血病（CML-CP）患者进行酪氨酸激酶抑制剂（TKI）治疗时的认知功能进行评估。对100例新诊断患者和584例接受TKI治疗超过1年的患者进行横断面评估，结果显示分别有31例（31.0%）和191例（32.7%）患者存在轻度认知障碍。在多变量分析中，较高比例的原始细胞与诊断时较差的MoCA评分相关[β = -0.29，95%置信区间（-0.54，-0.03），P = 0.027]；更深的分子反应[与<主要分子反应相比，β = 0.74（0.07，1.40），P = 0.029]，在TKI治疗时MoCA评分更好。在42例接受定期随访的患者中，TKI治疗12个月后观察到MoCA评分增加（P = 0.005）。较低的肿瘤负荷与CML-CP患者在诊断时和TKI治疗期间较好的认知功能相关。
